US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

266.44

+0.65000.24%

Post-market: 266.440.00000.00%19:30 EDT

Volume:51.13K

Turnover:13.62M

Market Cap:2.92B

PE:31.18

High:267.47

Open:267.37

Low:265.26

Close:265.79

52wk High:275.23

52wk Low:182.08

Shares:10.95M

Float Shares:10.95M

Volume Ratio:0.23

T/O Rate:0.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.05

PE(LYR):7.06

Loading ...

Overview Company News Filings

Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Veracyte Completes Convergent Genomics Acquisition to Expand Urology

Veracyte Buys Convergent Genomics

MT Newswires Live

Veracyte acquires Convergent Genomics for $150M in cash upfront

Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

THOMSON REUTERS

Veracyte, - Acquisition Includes $150 Mln Upfront Cash and up to $30 Mln Milestone Payments

THOMSON REUTERS

Veracyte, - Expects to Commercialize Initial Uroamp Test in Late 2028

THOMSON REUTERS

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Bruker Leadership Presents at Upcoming Wells Fargo Healthcare Conference

Video: Novartis slides after second recent drug development setback

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy

Mizuho survey shows no consensus into Alkermes ADHD data

Bruker Announces BRL 0.02 Dividend Per Unit for Q3 2026

Bruker BEST, Luvata Enter Strategic Collaboration to Supply RRP Superconductors for Fusion Magnets

Best and Luvata Announce Collaboration Agreement for Supply of High-Performance Rrp® Superconductors for Magnetic Confinement Fusion

THOMSON REUTERS

Corcept Names Roberto Vieira as President, Oncology in Initial Beneficial Ownership Filing

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

Veracyte Director Muna Bhanji Disposes of 1,864 Common Shares Worth $80,086.08

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/FBT/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":266.44,"timestamp":1790971200000,"preClose":265.79,"halted":0,"volume":51129,"hourTrading":{"tag":"盘后","latestPrice":266.44,"preClose":266.44,"latestTime":"19:30 EDT","volume":18,"amount":4793.6848,"timestamp":1790983804969,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.002445539711802465,"floatShares":10950002,"shares":10950002,"eps":8.545272,"marketStatus":"Market Closed","change":0.65,"latestTime":"10-02 16:00:00 EDT","open":267.37,"high":267.465,"low":265.2589,"amount":13615858.23858,"amplitude":0.0083,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":265.79,"sharesOutstanding":11450002,"nav":265.84,"aum":2897656531.68,"bidAskSpread":0.000914,"preHourTrading":{"tag":"盘前","latestPrice":265.84,"preClose":265.79,"latestTime":"07:07 EDT","volume":21,"amount":5569.2,"timestamp":1790939266223,"change":0.05,"changeRate":0.000188,"amplitude":0.008428},"postHourTrading":{"tag":"盘后","latestPrice":266.44,"preClose":266.44,"latestTime":"19:30 EDT","volume":18,"amount":4793.6848,"timestamp":1790983804969,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.23051848500740743,"impliedVol":0.2223,"impliedVolPercentile":0.6972},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10950002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.23051848500740743,"shares":10950002,"dividePrice":0,"high":267.465,"amplitude":0.0083,"preClose":265.79,"low":265.2589,"week52Low":182.08,"pbRate":"1.05","psRate":"703.82","week52High":275.23,"institutionHeld":0,"latestPrice":266.44,"eps":8.545272,"divideRate":0,"volume":51129,"delay":0,"ttmEps":8.545272,"open":267.37,"prevYearClose":206.52,"prevWeekClose":272.86,"prevMonthClose":272.26,"prevQuarterClose":272.26,"fiveDayClose":272.86,"twentyDayClose":273.79,"sixtyDayClose":256.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667444786","title":"Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667444786","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667444786?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (\"Legend Biotech\" or the \"Company\"), a global leader in cell therapy, today announced that its Board of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IBBQ","LFSC","GNOM","SYNB","LEGN","FBT","IBB","R","BK4232","BK4588","MEDI","BK4022","CNCR","XBI","BK4585","TBXU","BK4505","BK4139","CANC","MEMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695415","title":"Veracyte Completes Convergent Genomics Acquisition to Expand Urology","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695415","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695415?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:31","pubTimestamp":1789417898,"startTime":"0","endTime":"0","summary":"Veracyte ( ($VCYT) ) has shared an update. On Sept. 14, 2026, Veracyte completed the acquisition of Convergent Genomics Inc., a bladder cancer-focu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/veracyte-completes-convergent-genomics-acquisition-to-expand-urology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/veracyte-completes-convergent-genomics-acquisition-to-expand-urology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667373695","title":"Veracyte Buys Convergent Genomics","url":"https://stock-news.laohu8.com/highlight/detail?id=2667373695","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667373695?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:22","pubTimestamp":1789417352,"startTime":"0","endTime":"0","summary":"Veracyte  said late Monday it has acquired Convergent Genomics for $150 million in upfront cash and up to additional $30 million tied to milestones over UroAmp reimbursement efforts.The company said the acquisition expands its urology diagnostics portfolio with a urinary tumor DNA testing platform.Veracyte said it contemplated Convergent's operating expenses in 2026 adjusted EBITDA outlook and is not updating its guidance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695356","title":"Veracyte acquires Convergent Genomics for $150M in cash upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695356","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695356?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:10","pubTimestamp":1789416629,"startTime":"0","endTime":"0","summary":"Veracyte (VCYT) announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its propriet...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veracyte-acquires-convergent-genomics-for-150m-in-cash-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veracyte-acquires-convergent-genomics-for-150m-in-cash-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667768693","title":"Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2667768693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667768693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693761","title":"Veracyte, - Acquisition Includes $150 Mln Upfront Cash and up to $30 Mln Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693761?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667369376","title":"Veracyte, - Expects to Commercialize Initial Uroamp Test in Late 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2667369376","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667369376?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","PSIL","BK4139","ALKS","PSCH","MEDX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FXH","WDNA","JDOC","SBIO","BBH","GSKH","NVIB","MNTL","AZNH","LFSC","HRTS","GNOM","LLYX","IBRN","MEDI","PBPH","GNMX","MDTX","BBP","IBB","MEDX","GDOC","GPCR","PJP","BME","BIB","CANC","FBT","CURE","FHLC","TBXU","IBBQ","PTH","IEIH","IDNA","RSPH","XPH","JHMH","FTXH","CNCR","APXH","PSCH","IBBJ","SURI","PINK","SYNB","HYLG","PBE","PSIL","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666743153","title":"Bruker Leadership Presents at Upcoming Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666743153","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666743153?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:21","pubTimestamp":1788888090,"startTime":"0","endTime":"0","summary":"Bruker leadership presents at upcoming Wells Fargo healthcare conferenceBruker leadership to present at Wells Fargo’s 21st Annual Healthcare Conference in Boston on Sept. 9, 2026 at 8:00 a.m. ET.Morga","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL9m2WsZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BRKR","LU1815336091.USD","LU0757428866.USD","BK4121","TINY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665858375","title":"Video: Novartis slides after second recent drug development setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2665858375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665858375?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:05","pubTimestamp":1788872716,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","FBT","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MRNY","GSKH","FHLC","IBBQ","APXH","PSCH","HYLG","SURI","PSIL","GPCR","FTXH","LENZ","BBP","CURE","RSPH","PBPH","TBXU","AZNH","BIB","MEDI","GDOC","MEDX","BBH","IBB","NVIB","JHMH","LLYX","IBBJ","FBT","GNOM","HRTS","SYNB","JDOC","XPH","PINK","MNTL","MDTX","FXH","SBIO","LFSC","BME","PTH","PJP","CANC","WDNA","IBRN","GNMX","PBE","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665101723","title":"Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665101723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665101723?lang=en_us&edition=fundamental","pubTime":"2026-09-08 02:47","pubTimestamp":1788806848,"startTime":"0","endTime":"0","summary":"MILTON ESSEX S.A. ( ($PL:MTN) ) just unveiled an announcement. Milton Essex S.A., acting as sole shareholder of Sanford Biotech, has approved a PLN...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","GNOM","IBB","IBBQ","BK4585","BK4588","XBI","BK4581","MTNmain","CNCR","LFSC","FBT","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","PSIL","ADHD","ABVC","MEDX","BK4139","PSCH","IBRN","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665356339","title":"Bruker Announces BRL 0.02 Dividend Per Unit for Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665356339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665356339?lang=en_us&edition=fundamental","pubTime":"2026-09-05 02:15","pubTimestamp":1788545720,"startTime":"0","endTime":"0","summary":"Bruker announces BRL 0.02 dividend per unit for Q3 2026Bruker declared a Q3 2026 cash dividend of R$ 0.02 per unit for BRB2RKBDR 003.Shares trade with entitlement through Sept. 17.Payment is scheduled for Oct. 14.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL8CZ3L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU1815336091.USD","LU0757428866.USD","FBT","TINY","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338151","title":"Bruker BEST, Luvata Enter Strategic Collaboration to Supply RRP Superconductors for Fusion Magnets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338151","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664338151?lang=en_us&edition=fundamental","pubTime":"2026-09-04 14:01","pubTimestamp":1788501692,"startTime":"0","endTime":"0","summary":"Bruker BEST, Luvata enter strategic collaboration to supply RRP superconductors for fusion magnetsBruker’s BEST unit formed a strategic collaboration with Luvata Materials & Solutions to scale supply ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL7z0b9f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKR","LU1815336091.USD","TINY","LU0757428866.USD","BK4121","FBT","BRUKP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381329","title":"Best and Luvata Announce Collaboration Agreement for Supply of High-Performance Rrp® Superconductors for Magnetic Confinement Fusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664381329?lang=en_us&edition=fundamental","pubTime":"2026-09-04 14:00","pubTimestamp":1788501600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA2TXNVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BRKR","FBT","BK4121","TINY","LU0757428866.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800115","title":"Corcept Names Roberto Vieira as President, Oncology in Initial Beneficial Ownership Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800115","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664800115?lang=en_us&edition=fundamental","pubTime":"2026-09-04 08:40","pubTimestamp":1788482411,"startTime":"0","endTime":"0","summary":"Corcept names Roberto Vieira as President, Oncology in initial beneficial ownership filingCorcept Therapeutics President, Oncology Roberto Wandenkolk Vieira disclosed 4,068 common shares in an initial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL3ZgV8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","CORT","PSCH","LU0566484027.USD","BK4007","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802637","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802637","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802637?lang=en_us&edition=fundamental","pubTime":"2026-09-04 06:33","pubTimestamp":1788474793,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $97,651.34Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Sep. 3, 2026 at USD 48.01.D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5DSLJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","IBRN","MEDX","ALKS","PSIL","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664043388","title":"Veracyte Director Muna Bhanji Disposes of 1,864 Common Shares Worth $80,086.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2664043388","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664043388?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:49","pubTimestamp":1788468557,"startTime":"0","endTime":"0","summary":"Veracyte director Muna Bhanji disposes of 1,864 common shares worth $80,086.08Veracyte director Muna Bhanji sold 1,864 shares of common stock on Sep. 1, 2026 at $42.97.Direct holdings fell to 42,718 s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL4tYL9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Veracyte Director Muna Bhanji Disposes of 1,864 Common Shares Worth $80,086.08","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}